Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01357928 · ClinicalTrials.gov registry record
Thromboelastography (TEG) Reference Range Study
A clinical trial, sponsored by Haemonetics Corporation.
- Completed
- Registry status
- 159
- Enrollment target
NCT01357928: Completed study, sponsored by Haemonetics Corporation.
NCT01357928 is a clinical trial that has completed, run by Haemonetics Corporation. The registered enrollment target is 159 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01357928 has completed, sponsored by Haemonetics Corporation.
- COMPLETED
- Registry status
- 159 participants
- Enrollment target
Study Summary
As part of a system wide reagent verification plan Haemoscope Corporation will be running a study to verify the reference intervals of many of the reagents. Reference intervals will be constructed following the guidelines set out in CLSI document C28-A3c. This guideline calls for a reference interval to be constructed from at least 120 donors. Some reagents currently have ranges in place based on fewer donors than that stated in the guideline. This procedure will provide additional testing results to meet the requirements outlined in the CLSI guideline. Reagents that currently have no reference intervals will be tested and will include a minimum of 146 donors.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2011-04 |
| Est. Completion | 2011-10 |
What the finished NCT01357928 record still lists
NCT01357928 is an observational study that tracks outcomes without assigning an intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01357928 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01357928 about?
NCT01357928 is a clinical study titled "Thromboelastography (TEG) Reference Range Study". As part of a system wide reagent verification plan Haemoscope Corporation will be running a study to verify the reference intervals of many of the reagents. Reference intervals will be constructed following the guidelines set out in CLSI document C28-A3c. This guideline calls for a reference interva...
What is the current status of trial NCT01357928?
This trial is currently completed. The enrollment target is 159 participants. The study started on 2011-04. Estimated completion is 2011-10.
Who is sponsoring clinical trial NCT01357928?
This trial is sponsored by Haemonetics Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia